Free Trial
→ Trump Orders 'National Digital Asset Stockpile' (From Crypto 101 Media) (Ad) Buy DVAX Stock  Free DVAX Stock Alerts

Dynavax Technologies (DVAX) Financials

Dynavax Technologies logo
$11.33 -0.15 (-1.31%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$11.26 -0.07 (-0.66%)
As of 05/2/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Dynavax Technologies

Annual Income Statements for Dynavax Technologies

This table shows Dynavax Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -91 -107 -112 -95 -159 -156 -75 72 293 -6.39 27
Consolidated Net Income / (Loss)		 -91 -107 -112 -95 -159 -153 -75 77 293 -6.39 27
Net Income / (Loss) Continuing Operations		 -91 -107 -112 -95 -159 -153 -75 77 293 -6.39 27
Total Pre-Tax Income 		-91 -105 -110 -95 -159 -153 -75 78 294 -4.37 31
Total Operating Income		 -91 -105 -111 -96 -153 -135 -68 134 284 -37 -4.12
Total Gross Profit		 11 4.05 11 0.33 -2.74 25 35 266 461 182 228
Total Revenue		 11 4.05 11 0.33 8.20 35 47 439 723 232 277
Operating Revenue		 11 4.05 11 0.33 8.20 35 47 439 723 232 277
Total Cost of Revenue		 0.00 0.00 0.00 0.00 11 10 11 174 262 50 49
Operating Cost of Revenue		 - - - - 11 10 11 174 262 50 49
Total Operating Expenses		 102 109 122 96 151 160 104 131 177 219 232
Selling, General & Admin Expense		 17 22 37 27 65 75 79 100 131 153 170
Research & Development Expense		 85 87 84 65 75 62 29 32 47 55 62
Other Operating Expenses / (Income)		 - - - - - - - 0.00 0.00 12 0.00
Other Special Charges / (Income)		 - - - - 0.00 0.00 -6.85 -1.00 -1.00 -1.00 0.00
Total Other Income / (Expense), net		 0.16 -0.37 0.76 1.34 -5.51 -18 -6.87 -57 11 33 35
Interest Expense		 0.04 0.57 - - 9.34 17 19 16 6.73 6.76 6.79
Interest & Investment Income		 0.19 0.21 0.76 1.34 3.83 5.99 8.97 7.88 16 40 41
Other Income / (Expense), net		 - - - - 0.00 -6.77 3.23 -48 1.80 -0.15 0.29
Income Tax Expense		 - - - - - 0.00 0.00 0.81 1.14 2.02 3.55
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - 0.00 0.00 4.57 0.28 0.00 0.00
Basic Earnings per Share		 ($3.45) ($3.25) ($2.92) ($1.81) ($2.55) ($2.16) ($0.75) $0.62 $2.32 ($0.05) $0.21
Weighted Average Basic Shares Outstanding		 26.29M 32.88M 38.51M 52.61M 62.36M 72.02M 100.75M 116.26M 126.40M 128.73M 130.05M
Diluted Earnings per Share		 ($3.45) ($3.25) ($2.92) ($1.81) ($2.55) ($2.16) ($0.78) $0.57 $1.97 ($0.05) $0.20
Weighted Average Diluted Shares Outstanding		 26.29M 32.88M 38.51M 52.61M 62.36M 72.02M 101.50M 133.01M 150.80M 128.73M 133.34M
Weighted Average Basic & Diluted Shares Outstanding		 26.29M 32.88M 38.51M 52.61M 62.36M 72.02M 113.26M 124.92M 127.69M 130.61M 124.07M

Quarterly Income Statements for Dynavax Technologies

This table shows Dynavax Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 64 67 -24 3.43 14 0.22 -8.72 11 18 7.05
Consolidated Net Income / (Loss)		 64 68 -24 3.43 14 0.22 -8.72 11 18 7.05
Net Income / (Loss) Continuing Operations		 64 68 -24 3.43 14 0.22 -8.72 11 17 7.20
Total Pre-Tax Income 		64 68 -24 4.21 14 1.00 -11 15 20 7.63
Total Operating Income		 61 63 -30 -3.41 5.12 -8.49 -18 5.20 10 -1.63
Total Gross Profit		 106 107 32 47 56 47 40 62 68 59
Total Revenue		 168 184 47 60 70 56 51 74 81 72
Operating Revenue		 168 184 47 60 70 56 51 74 81 72
Total Cost of Revenue		 61 77 15 14 13 8.69 11 12 13 13
Operating Cost of Revenue		 61 77 15 14 13 8.69 11 12 13 13
Total Operating Expenses		 45 44 62 50 51 55 58 57 57 60
Selling, General & Admin Expense		 32 31 37 37 38 41 44 42 43 42
Research & Development Expense		 13 13 14 13 14 14 14 15 14 19
Total Other Income / (Expense), net		 2.90 4.56 6.53 7.61 9.03 9.49 6.27 9.71 9.89 9.11
Interest Expense		 1.69 1.68 1.69 1.69 1.69 1.69 1.70 1.70 1.70 1.70
Interest & Investment Income		 4.59 6.35 6.60 7.38 8.46 17 9.47 9.20 9.38 13
Other Income / (Expense), net		 0.00 -0.11 1.62 1.92 2.26 -5.95 -1.50 2.21 2.21 -2.62
Income Tax Expense		 0.28 0.24 0.62 0.78 -0.15 0.78 -2.78 3.52 2.22 0.58
Basic Earnings per Share		 $0.50 $0.54 ($0.19) $0.03 $0.11 - ($0.07) $0.09 $0.13 $0.06
Weighted Average Basic Shares Outstanding		 127.06M 126.40M 127.92M 128.63M 128.99M 128.73M 130.20M 130.92M 131.13M 130.05M
Diluted Earnings per Share		 $0.43 $0.45 ($0.19) $0.03 $0.10 $0.01 ($0.07) $0.08 $0.12 $0.07
Weighted Average Diluted Shares Outstanding		 151.54M 150.80M 127.92M 152.14M 154.20M 128.73M 130.20M 154.47M 154.81M 133.34M
Weighted Average Basic & Diluted Shares Outstanding		 127.58M 127.69M 128.49M 128.80M 129.26M 130.61M 130.89M 131.04M 131.45M 124.07M

Annual Cash Flow Statements for Dynavax Technologies

This table details how cash moves in and out of Dynavax Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 26 -4.70 -21 2.32 23 39 -7.79 404 -234 -52 -54
Net Cash From Operating Activities		 -74 -93 -107 -78 -131 -121 -92 336 63 101 67
Net Cash From Continuing Operating Activities		 -74 -93 -107 -78 -131 -87 -92 336 63 101 67
Net Income / (Loss) Continuing Operations		 -91 -107 -112 -95 -159 -153 -75 77 293 -6.39 27
Consolidated Net Income / (Loss)		 -91 -107 -112 -95 -159 -153 -75 77 293 -6.39 27
Depreciation Expense		 1.40 1.37 2.26 3.24 3.62 8.94 4.27 4.30 3.81 4.34 4.63
Amortization Expense		 0.88 0.66 0.18 1.00 9.30 11 5.60 3.23 -1.33 -14 -11
Non-Cash Adjustments To Reconcile Net Income		 6.73 11 16 15 26 33 -23 74 201 51 57
Changes in Operating Assets and Liabilities, net		 7.97 1.12 -13 -1.31 -12 13 -3.49 177 -434 65 -12
Net Cash From Investing Activities		 91 -86 86 -109 55 -43 -27 14 -316 -154 -18
Net Cash From Continuing Investing Activities		 91 -86 86 -109 55 -29 -27 14 -316 -154 -18
Purchase of Property, Plant & Equipment		 -1.67 -6.97 -7.76 -0.67 -4.19 -22 -4.07 -9.48 -7.14 -4.10 -6.35
Purchase of Investments		 -45 -209 -127 -228 -214 -215 -202 -165 -632 -637 -524
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 6.85 1.00 1.00 1.00 0.00
Sale and/or Maturity of Investments		 137 130 221 120 284 202 179 188 322 486 512
Net Cash From Financing Activities		 9.90 174 0.53 188 99 154 109 56 20 1.39 -102
Net Cash From Continuing Financing Activities		 9.90 174 0.53 188 99 154 109 56 20 1.39 -102
Repurchase of Common Equity		 - - - - - - - - 0.00 0.00 -100
Issuance of Common Equity		 0.29 184 0.62 186 0.59 67 109 47 9.89 1.54 1.76
Other Financing Activities, net		 0.05 0.53 -0.08 1.61 -0.52 0.00 0.29 -21 9.64 -0.15 -3.78
Other Net Changes in Cash		 - - -0.26 0.70 - - - -1.43 - 0.32 -0.86
Cash Interest Paid		 - 0.72 - - 6.58 12 17 9.82 5.64 5.64 5.64
Cash Income Taxes Paid		 - - - - - 0.00 0.00 1.31 2.21 2.01 4.59

Quarterly Cash Flow Statements for Dynavax Technologies

This table details how cash moves in and out of Dynavax Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -51 3.45 -28 52 -72 -4.22 -18 -20 6.84 -23
Net Cash From Operating Activities		 62 35 28 28 31 14 -17 11 19 53
Net Cash From Continuing Operating Activities		 62 35 28 28 31 14 -17 11 19 53
Net Income / (Loss) Continuing Operations		 64 68 -24 3.43 14 0.22 -8.72 11 18 7.05
Consolidated Net Income / (Loss)		 64 68 -24 3.43 14 0.22 -8.72 11 18 7.05
Depreciation Expense		 0.89 0.84 1.01 1.10 1.12 1.11 1.12 1.14 1.18 1.18
Amortization Expense		 0.77 -1.60 -2.86 -3.07 -3.30 -4.40 -3.70 -3.09 -2.56 -1.77
Non-Cash Adjustments To Reconcile Net Income		 65 39 23 8.55 10 9.19 20 11 6.78 20
Changes in Operating Assets and Liabilities, net		 -68 -71 31 18 8.60 7.64 -25 -10 -3.53 27
Net Cash From Investing Activities		 -119 -33 -52 25 -106 -20 2.83 -29 -15 23
Net Cash From Continuing Investing Activities		 -119 -33 -52 25 -106 -20 2.83 -29 -15 23
Purchase of Property, Plant & Equipment		 -1.28 -1.59 -1.28 -0.75 -0.35 -1.72 -0.75 -0.78 -1.35 -3.48
Purchase of Investments		 -201 -118 -185 -74 -225 -153 -151 -175 -165 -33
Sale and/or Maturity of Investments		 83 86 134 100 118 134 154 147 151 60
Net Cash From Financing Activities		 8.06 0.15 -3.09 -0.29 2.99 1.78 -4.20 -1.42 2.48 -99
Net Cash From Continuing Financing Activities		 8.06 0.15 -3.09 -0.29 2.99 1.78 -4.20 -1.42 2.48 -99
Other Financing Activities, net		 7.34 0.15 -3.87 -0.29 2.24 1.78 -5.11 -1.42 1.62 1.13
Cash Interest Paid		 - 2.82 0.00 2.82 - 2.82 0.00 2.82 - 2.82
Cash Income Taxes Paid		 0.28 1.42 0.03 0.68 0.70 0.60 0.95 2.01 1.61 0.01

Annual Balance Sheets for Dynavax Technologies

This table presents Dynavax Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 138 217 110 219 211 279 353 1,039 986 997 986
Total Current Assets		 127 200 90 198 174 209 290 973 917 859 849
Cash & Equivalents		 50 45 24 27 49 40 32 436 202 150 96
Short-Term Investments		 73 151 57 165 96 111 133 110 422 592 618
Accounts Receivable		 0.73 1.39 1.34 0.85 3.70 8.89 23 132 148 45 47
Inventories, net		 - - - 0.31 19 41 64 61 59 53 70
Prepaid Expenses		 4.06 2.43 6.84 3.70 6.10 7.38 39 233 86 19 18
Plant, Property, & Equipment, net		 7.92 14 17 17 17 32 31 35 38 37 39
Total Noncurrent Assets		 2.93 2.88 2.91 4.14 19 38 33 32 31 101 98
Goodwill		 2.28 2.04 1.97 2.24 2.14 2.08 2.30 2.13 2.01 2.07 1.95
Other Noncurrent Operating Assets		 0.02 0.23 0.33 1.27 4.98 34 30 29 29 99 96
Total Liabilities & Shareholders' Equity		 138 217 110 219 211 279 353 1,039 986 997 986
Total Liabilities		 38 30 20 19 148 271 295 817 405 375 389
Total Current Liabilities		 20 29 20 19 38 53 77 556 150 62 79
Accounts Payable		 1.16 3.43 3.80 4.54 5.28 9.28 3.31 2.60 3.21 5.25 9.06
Accrued Expenses		 13 23 16 14 26 19 22 54 35 52 65
Other Current Liabilities		 - - - - 7.00 25 14 149 111 4.52 4.20
Total Noncurrent Liabilities		 18 0.77 0.44 0.64 110 218 217 260 255 313 311
Long-Term Debt		 9.56 - - - 101 179 180 220 222 223 224
Other Noncurrent Operating Liabilities		 1.07 0.77 0.44 0.64 8.92 39 37 40 33 90 87
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 100 187 89 200 63 8.29 59 222 581 622 597
Total Preferred & Common Equity		 100 187 89 200 63 8.29 59 222 581 622 597
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 100 187 89 200 63 8.29 59 222 581 622 597
Common Stock		 695 890 905 1,108 1,131 1,230 1,352 1,442 1,511 1,555 1,505
Retained Earnings		 -593 -700 -812 -907 -1,066 -1,219 -1,294 -1,217 -924 -931 -903
Accumulated Other Comprehensive Income / (Loss)		 -1.67 -2.93 -3.62 -0.88 -2.02 -2.39 0.27 -2.27 -5.44 -2.11 -4.72

Quarterly Balance Sheets for Dynavax Technologies

This table presents Dynavax Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 999 970 936 973 987 1,016 1,062
Total Current Assets		 933 830 797 836 851 882 926
Cash & Equivalents		 199 174 227 155 132 113 119
Short-Term Investments		 388 478 455 566 592 623 645
Accounts Receivable		 131 105 45 47 46 63 75
Inventories, net		 103 58 53 49 62 62 62
Prepaid Expenses		 113 16 17 19 20 21 25
Plant, Property, & Equipment, net		 35 38 37 36 36 36 37
Total Noncurrent Assets		 31 102 102 101 99 98 98
Goodwill		 1.84 2.04 2.04 1.98 2.02 2.01 2.09
Other Noncurrent Operating Assets		 29 99 99 99 97 96 96
Total Liabilities & Shareholders' Equity		 999 970 936 973 987 1,016 1,062
Total Liabilities		 499 406 359 368 368 373 381
Total Current Liabilities		 244 92 45 54 56 62 70
Accounts Payable		 3.05 7.30 3.25 3.12 2.43 4.56 7.09
Accrued Expenses		 43 33 37 47 49 53 59
Other Current Liabilities		 111 51 4.15 4.39 4.59 4.57 4.44
Total Noncurrent Liabilities		 255 315 314 314 312 311 311
Long-Term Debt		 221 222 222 222 223 223 224
Other Noncurrent Operating Liabilities		 33 93 92 91 89 88 87
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 501 564 577 605 618 643 681
Total Preferred & Common Equity		 501 564 577 605 618 643 681
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 501 564 577 605 618 643 681
Common Stock		 1,502 1,516 1,528 1,542 1,562 1,576 1,591
Retained Earnings		 -992 -949 -945 -931 -939 -928 -910
Accumulated Other Comprehensive Income / (Loss)		 -9.26 -4.20 -5.37 -5.96 -4.37 -4.91 0.51

Annual Metrics and Ratios for Dynavax Technologies

This table displays calculated financial ratios and metrics derived from Dynavax Technologies' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.95% -63.29% 172.67% -97.04% 2,407.03% 329.60% 32.18% 844.00% 64.45% -67.86% 19.36%
EBITDA Growth		 -38.59% -15.75% -5.07% 15.25% -53.00% 13.43% 54.52% 269.31% 207.55% -116.14% 77.78%
EBIT Growth		 -37.33% -15.07% -5.36% 13.28% -59.70% 7.64% 54.00% 232.10% 231.56% -113.03% 89.70%
NOPAT Growth		 -37.33% -15.07% -5.36% 13.28% -59.70% 12.05% 49.30% 378.07% 112.21% -109.18% 85.92%
Net Income Growth		 -35.97% -17.72% -5.29% 15.38% -66.99% 3.96% 50.69% 201.96% 282.15% -102.18% 527.44%
EPS Growth		 9.92% 5.80% 10.15% 38.01% -40.88% 15.29% 63.89% 173.08% 245.61% -102.54% 500.00%
Operating Cash Flow Growth		 -25.68% -25.52% -15.66% 27.59% -69.38% 7.65% 23.92% 463.71% -81.31% 60.35% -33.86%
Free Cash Flow Firm Growth		 -1.24% -41.75% -22.29% 28.89% -75.95% 4.92% 23.84% 462.25% -99.70% 5,314.81% -116.06%
Invested Capital Growth		 -253.71% 27.09% 174.41% -1.64% 151.64% 100.33% 105.59% -241.07% 272.50% -42.50% 4.25%
Revenue Q/Q Growth		 -4.91% -28.22% 148.94% -95.70% 182.59% -7.97% 59.04% 66.50% -1.44% -35.69% 6.30%
EBITDA Q/Q Growth		 -11.86% -4.56% 6.92% -9.09% -6.84% 3.70% 23.46% 523.35% -12.82% -238.53% 55.55%
EBIT Q/Q Growth		 -11.50% -4.51% 6.44% -9.74% -7.07% 2.62% 22.32% 408.08% -11.69% -192.27% 72.70%
NOPAT Q/Q Growth		 -11.50% -4.51% 6.44% -9.74% -7.07% 7.27% 18.47% 354.03% -6.20% -176.74% 60.70%
Net Income Q/Q Growth		 -11.33% -4.48% 4.36% -6.35% -8.57% 2.06% 22.05% 299.08% -9.85% -110.45% 33.36%
EPS Q/Q Growth		 -0.88% -16.07% 4.26% -16.77% -9.44% 10.37% 40.91% 1,050.00% -14.35% -112.82% 42.86%
Operating Cash Flow Q/Q Growth		 -7.31% -5.69% -4.32% 9.92% -13.76% 8.05% 7.30% 68.36% -57.70% -17.40% 143.93%
Free Cash Flow Firm Q/Q Growth		 -3.81% -10.37% -3.59% 10.86% -12.85% 11.29% 4.11% 36.08% -97.66% -19.75% 81.55%
Invested Capital Q/Q Growth		 -37.40% 4.63% 479.30% -41.74% 7.84% -13.56% 2.24% 18.39% 31.80% -4.16% -24.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% -33.37% 71.12% 75.49% 60.50% 63.73% 78.40% 82.17%
EBITDA Margin		 -806.98% -2,544.40% -980.46% -28,061.16% -1,712.55% -345.11% -118.74% 21.30% 39.83% -20.00% -3.72%
Operating Margin		 -827.69% -2,594.40% -1,002.51% -29,359.33% -1,870.20% -382.87% -146.87% 30.60% 39.23% -15.94% -1.49%
EBIT Margin		 -827.69% -2,594.40% -1,002.51% -29,359.33% -1,870.20% -402.09% -139.94% 19.58% 39.48% -16.01% -1.38%
Profit (Net Income) Margin		 -822.35% -2,636.89% -1,018.24% -29,099.08% -1,938.27% -433.29% -161.63% 17.46% 40.57% -2.75% 9.85%
Tax Burden Percent		 99.53% 101.28% 102.27% 100.51% 100.04% 100.00% 100.00% 98.96% 99.61% 146.30% 88.51%
Interest Burden Percent		 99.83% 100.35% 99.32% 98.61% 103.59% 107.76% 115.50% 90.08% 103.15% 11.75% -805.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.04% 0.39% 0.00% 11.49%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -943.21% -863.87% -353.51% -87.94% 0.00% 754.22% -18.47% -3.49%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -922.84% -820.49% 294.92% -218.73% 0.00% 751.27% -22.70% -9.62%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 877.30% 742.86% -74.21% -136.72% 0.00% -681.24% 17.41% 7.97%
Return on Equity (ROE)		 -63.27% -74.28% -81.40% -65.91% -121.01% -427.72% -224.65% 54.59% 72.98% -1.06% 4.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,313.11% -941.55% -950.12% -420.33% -157.04% 0.00% 0.52% 35.49% -7.64%
Operating Return on Assets (OROA)		 -53.26% -59.21% -67.85% -58.46% -71.37% -57.81% -20.60% 12.36% 28.18% -3.75% -0.39%
Return on Assets (ROA)		 -52.91% -60.18% -68.92% -57.94% -73.96% -62.29% -23.80% 11.02% 28.95% -0.64% 2.75%
Return on Common Equity (ROCE)		 -63.27% -74.28% -81.40% -65.91% -121.01% -427.72% -224.65% 54.59% 72.98% -1.06% 4.48%
Return on Equity Simple (ROE_SIMPLE)		 -90.29% -57.09% -126.06% -47.68% -251.96% -1,840.77% -128.19% 34.50% 50.46% -1.03% 4.58%
Net Operating Profit after Tax (NOPAT)		 -64 -74 -77 -67 -107 -94 -48 133 282 -26 -3.65
NOPAT Margin		 -579.38% -1,816.08% -701.76% -20,551.53% -1,309.14% -268.01% -102.81% 30.28% 39.08% -11.16% -1.32%
Net Nonoperating Expense Percent (NNEP)		 -17.65% -21.42% -25.08% -20.36% -43.38% -648.43% 130.79% -36.24% 2.95% 4.23% 6.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 35.19% -3.07% -0.44%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 133.37% 28.88% 24.51% 39.50% 36.28% 21.60% 17.83%
SG&A Expenses to Revenue		 157.51% 547.65% 337.38% 8,369.11% 790.07% 212.91% 170.26% 22.79% 18.18% 65.84% 61.45%
R&D to Revenue		 766.68% 2,146.74% 765.13% 19,874.01% 914.26% 176.98% 61.45% 7.33% 6.45% 23.63% 22.20%
Operating Expenses to Revenue		 927.69% 2,694.40% 1,102.51% 29,459.33% 1,836.83% 453.99% 222.36% 29.90% 24.49% 94.34% 83.65%
Earnings before Interest and Taxes (EBIT)		 -91 -105 -111 -96 -153 -142 -65 86 285 -37 -3.83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -89 -103 -108 -92 -140 -122 -55 94 288 -46 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.41 4.96 1.71 5.68 9.10 57.87 8.35 7.59 2.34 2.90 2.81
Price to Tangible Book Value (P/TBV)		 4.51 5.02 1.74 5.74 11.66 129.34 8.69 7.66 2.34 2.91 2.82
Price to Revenue (P/Rev)		 40.18 229.22 13.78 3,465.29 69.97 13.62 10.53 3.84 1.88 7.78 6.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.39 4.64 0.00 61.47
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.27% 21.57% 0.00% 1.63%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 9.85 133.21 29.75 14.24 6.90 0.00 5.36 12.56 11.13
Enterprise Value to Revenue (EV/Rev)		 29.93 180.80 6.41 2,878.58 64.52 14.40 10.85 3.10 1.32 5.54 4.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.56 3.32 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.83 3.35 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.24 3.38 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.06 15.22 12.80 17.87
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.40 1,037.87 25.85 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.00 0.00 0.00 1.60 21.54 3.06 0.99 0.38 0.36 0.38
Long-Term Debt to Equity		 0.10 0.00 0.00 0.00 1.60 21.54 3.06 0.99 0.38 0.36 0.38
Financial Leverage		 -1.06 -1.08 -1.01 -0.95 -0.91 -0.25 0.63 -1.11 -0.91 -0.77 -0.83
Leverage Ratio		 1.20 1.23 1.18 1.14 1.64 6.87 9.44 4.95 2.52 1.65 1.63
Compound Leverage Factor		 1.19 1.24 1.17 1.12 1.69 7.40 10.90 4.46 2.60 0.19 -13.11
Debt to Total Capital		 8.69% 0.00% 0.00% 0.00% 61.53% 95.56% 75.39% 49.79% 27.61% 26.36% 27.28%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 8.69% 0.00% 0.00% 0.00% 61.53% 95.56% 75.39% 49.79% 27.61% 26.36% 27.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.31% 100.00% 100.00% 100.00% 38.47% 4.44% 24.61% 50.21% 72.39% 73.64% 72.72%
Debt to EBITDA		 -0.11 0.00 0.00 0.00 -0.72 -1.47 -3.25 2.36 0.77 -4.79 -21.69
Net Debt to EBITDA		 1.27 0.00 0.00 0.00 0.32 -0.23 -0.27 -3.48 -1.40 11.18 47.47
Long-Term Debt to EBITDA		 -0.11 0.00 0.00 0.00 -0.72 -1.47 -3.25 2.36 0.77 -4.79 -21.69
Debt to NOPAT		 -0.15 0.00 0.00 0.00 -0.94 -1.89 -3.76 1.66 0.78 -8.59 -61.36
Net Debt to NOPAT		 1.77 0.00 0.00 0.00 0.42 -0.29 -0.31 -2.45 -1.43 20.05 134.30
Long-Term Debt to NOPAT		 -0.15 0.00 0.00 0.00 -0.94 -1.89 -3.76 1.66 0.78 -8.59 -61.36
Altman Z-Score		 -0.14 13.69 -8.38 29.08 -6.33 -5.93 -3.88 0.78 3.32 2.65 2.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.28 6.95 4.47 10.65 4.58 3.93 3.75 1.75 6.11 13.81 10.80
Quick Ratio		 6.08 6.86 4.13 10.36 3.92 3.02 2.42 1.22 5.14 12.65 9.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -54 -77 -94 -67 -118 -112 -85 310 0.92 50 -8.00
Operating Cash Flow to CapEx		 -4,423.40% -1,327.96% -1,380.06% -11,587.15% -3,135.92% -541.28% 0.00% 3,958.10% 1,021.60% 3,239.79% 1,047.10%
Free Cash Flow to Firm to Interest Expense		 -1,554.82 -134.86 0.00 0.00 -12.64 -6.61 -4.48 18.87 0.14 7.37 -1.18
Operating Cash Flow to Interest Expense		 -2,106.80 -161.82 0.00 0.00 -14.06 -7.14 -4.84 20.45 9.32 14.88 9.79
Operating Cash Flow Less CapEx to Interest Expense		 -2,154.43 -174.00 0.00 0.00 -14.51 -8.46 -4.69 19.93 8.40 14.42 8.85
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.02 0.07 0.00 0.04 0.14 0.15 0.63 0.71 0.23 0.28
Accounts Receivable Turnover		 9.37 3.82 8.07 0.30 3.60 5.59 2.95 5.69 5.17 2.42 6.06
Inventory Turnover		 0.00 0.00 0.00 0.00 1.13 0.34 0.22 2.78 4.34 0.89 0.80
Fixed Asset Turnover		 1.33 0.37 0.71 0.02 0.49 1.44 1.49 13.40 19.90 6.20 7.27
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 2.23 1.40 1.81 58.72 90.23 11.87 6.91
Days Sales Outstanding (DSO)		 38.94 95.58 45.22 1,225.60 101.47 65.24 123.68 64.15 70.54 150.89 60.19
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 322.70 1,082.84 1,679.78 131.45 84.08 410.12 455.26
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 163.86 261.16 201.37 6.22 4.05 30.76 52.80
Cash Conversion Cycle (CCC)		 38.94 95.58 45.22 1,225.60 260.32 886.92 1,602.09 189.39 150.58 530.24 462.65
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -13 -9.66 7.18 7.07 18 36 73 -103 178 102 107
Invested Capital Turnover		 -1.30 -0.35 -8.94 0.05 0.66 1.32 0.86 -29.22 19.30 1.66 2.65
Increase / (Decrease) in Invested Capital		 -9.50 3.59 17 -0.12 11 18 38 -177 282 -76 4.35
Enterprise Value (EV)		 330 732 71 941 529 507 505 1,362 955 1,287 1,189
Market Capitalization		 443 928 152 1,133 574 480 490 1,688 1,358 1,807 1,679
Book Value per Share		 $0.38 $4.87 $2.32 $3.29 $1.01 $0.10 $0.53 $1.85 $4.55 $4.81 $4.54
Tangible Book Value per Share		 $0.37 $4.82 $2.26 $3.26 $0.78 $0.04 $0.51 $1.84 $4.54 $4.80 $4.53
Total Capital		 110 187 89 200 164 187 239 443 803 845 821
Total Debt		 9.56 0.00 0.00 0.00 101 179 180 220 222 223 224
Total Long-Term Debt		 9.56 0.00 0.00 0.00 101 179 180 220 222 223 224
Net Debt		 -113 -196 -81 -192 -45 28 15 -325 -403 -520 -490
Capital Expenditures (CapEx)		 1.67 6.97 7.76 0.67 4.19 22 -2.78 8.48 6.14 3.10 6.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -25 -12 -12 -9.21 4.55 48 -130 143 55 56
Debt-free Net Working Capital (DFNWC)		 107 171 70 179 136 156 213 416 767 797 770
Net Working Capital (NWC)		 107 171 70 179 136 156 213 416 767 797 770
Net Nonoperating Expense (NNE)		 27 33 35 28 52 58 27 56 -11 -20 -31
Net Nonoperating Obligations (NNO)		 -114 -197 -82 -192 -45 27 15 -326 -403 -520 -490
Total Depreciation and Amortization (D&A)		 2.29 2.03 2.44 4.25 13 20 9.87 7.53 2.49 -9.28 -6.49
Debt-free, Cash-free Net Working Capital to Revenue		 -140.45% -616.40% -107.33% -3,799.39% -112.28% 12.92% 102.18% -29.54% 19.72% 23.52% 20.37%
Debt-free Net Working Capital to Revenue		 971.34% 4,226.20% 629.93% 54,871.56% 1,662.98% 441.82% 456.71% 94.69% 106.12% 343.08% 277.84%
Net Working Capital to Revenue		 971.34% 4,226.20% 629.93% 54,871.56% 1,662.98% 441.82% 456.71% 94.69% 106.12% 343.08% 277.84%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.45) ($3.25) ($2.92) ($1.81) ($2.55) ($2.16) ($0.75) $0.62 $2.32 ($0.05) $0.21
Adjusted Weighted Average Basic Shares Outstanding		 28.91M 38.48M 44.35M 61.68M 64.00M 86.19M 100.75M 116.26M 126.40M 128.73M 130.05M
Adjusted Diluted Earnings per Share		 ($3.45) ($3.25) ($2.92) ($1.81) ($2.55) ($2.16) ($0.78) $0.57 $1.97 ($0.05) $0.20
Adjusted Weighted Average Diluted Shares Outstanding		 28.91M 38.48M 44.35M 61.68M 64.00M 86.19M 101.50M 133.01M 150.80M 128.73M 133.34M
Adjusted Basic & Diluted Earnings per Share		 ($3.45) ($3.25) ($2.92) ($1.81) ($2.55) ($2.16) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.29M 32.88M 38.51M 52.61M 62.36M 72.02M 113.26M 124.92M 127.69M 130.61M 124.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -64 -74 -77 -65 -107 -85 -53 132 281 -27 -3.65
Normalized NOPAT Margin		 -576.94% -1,816.08% -701.76% -19,955.78% -1,309.14% -241.46% -113.11% 30.06% 38.94% -11.46% -1.32%
Pre Tax Income Margin		 -826.28% -2,603.46% -995.67% -28,950.46% -1,937.41% -433.29% -161.63% 17.64% 40.72% -1.88% 11.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,608.89 -183.69 0.00 0.00 -16.42 -8.34 -3.42 5.24 42.38 -5.50 -0.56
NOPAT to Interest Expense		 -1,826.22 -128.59 0.00 0.00 -11.49 -5.56 -2.51 8.11 41.95 -3.84 -0.54
EBIT Less CapEx to Interest Expense		 -2,656.51 -195.88 0.00 0.00 -16.87 -9.66 -3.27 4.73 41.47 -5.96 -1.50
NOPAT Less CapEx to Interest Expense		 -1,873.85 -140.77 0.00 0.00 -11.94 -6.88 -2.37 7.59 41.04 -4.30 -1.47
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 366.18%

Quarterly Metrics and Ratios for Dynavax Technologies

This table displays calculated financial ratios and metrics derived from Dynavax Technologies' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 54.92% -5.42% -58.83% -76.51% -58.56% -69.87% 8.24% 22.48% 15.99% 29.56%
EBITDA Growth		 317.52% -40.47% -189.05% -102.69% -91.76% -128.47% 28.29% 257.60% 110.09% 72.75%
EBIT Growth		 313.07% -37.47% -187.63% -101.16% -87.99% -122.92% 32.69% 599.19% 66.60% 70.59%
NOPAT Growth		 443.46% -22.06% -168.83% -102.18% -91.54% -102.97% 41.26% 242.98% 73.15% 19.16%
Net Income Growth		 324.44% -32.12% -174.05% -97.34% -77.60% -99.68% 64.16% 231.86% 23.10% 3,119.18%
EPS Growth		 279.17% -42.31% -186.36% -96.55% -76.74% -97.78% 63.16% 166.67% 20.00% 600.00%
Operating Cash Flow Growth		 -7.02% -71.00% 154.76% 68.43% -49.43% -60.61% -160.38% -61.80% -37.46% 285.09%
Free Cash Flow Firm Growth		 -195.80% -184.97% -306.02% 112.52% 116.67% 133.79% 102.04% -275.98% -175.11% -107.93%
Invested Capital Growth		 206.81% 272.50% 2,672.10% -6.26% -20.92% -42.50% -11.61% 10.97% 31.88% 4.25%
Revenue Q/Q Growth		 -34.60% 9.99% -74.57% 28.39% 15.38% -20.02% -8.64% 45.29% 9.26% -10.66%
EBITDA Q/Q Growth		 -50.84% -1.26% -148.93% 88.66% 250.36% -441.27% -38.85% 124.92% 100.44% -144.26%
EBIT Q/Q Growth		 -52.12% 2.66% -145.42% 94.82% 597.30% -295.86% -54.75% 138.42% 65.97% -134.58%
NOPAT Q/Q Growth		 -52.10% 2.92% -133.66% 86.88% 286.15% -136.12% -566.22% 131.92% 125.43% -116.86%
Net Income Q/Q Growth		 -50.44% 6.15% -135.92% 114.10% 316.58% -98.47% -4,082.19% 230.56% 54.52% -59.93%
EPS Q/Q Growth		 -50.57% 4.65% -142.22% 115.79% 233.33% -90.00% -800.00% 214.29% 50.00% -41.67%
Operating Cash Flow Q/Q Growth		 269.71% -43.23% -20.96% 1.54% 10.99% -55.78% -221.16% 164.23% 81.71% 172.31%
Free Cash Flow Firm Q/Q Growth		 -394.98% -8.94% 31.48% 103.39% 559.01% 120.76% -95.86% -392.29% -181.27% 76.68%
Invested Capital Q/Q Growth		 7.77% 31.80% -25.13% -11.86% -9.09% -4.16% 15.09% 10.67% 8.04% -24.24%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 63.43% 58.00% 68.65% 77.53% 80.97% 84.37% 78.41% 83.76% 83.77% 81.38%
EBITDA Margin		 37.60% 33.75% -64.93% -5.73% 7.47% -31.89% -43.02% 7.38% 13.54% -6.71%
Operating Margin		 36.60% 34.22% -64.46% -5.65% 7.36% -15.27% -34.99% 7.04% 12.50% -2.27%
EBIT Margin		 36.60% 34.16% -61.01% -2.46% 10.61% -25.98% -37.94% 10.03% 15.24% -5.90%
Profit (Net Income) Margin		 38.04% 36.71% -51.85% 5.69% 20.56% 0.39% -17.17% 15.43% 21.82% 9.79%
Tax Burden Percent		 99.56% 99.65% 102.60% 81.55% 101.04% 21.99% 75.85% 76.39% 88.78% 92.42%
Interest Burden Percent		 104.39% 107.84% 82.84% -283.68% 191.81% -6.90% 59.66% 201.35% 161.29% -179.52%
Effective Tax Rate		 0.44% 0.35% 0.00% 18.45% -1.04% 78.01% 0.00% 23.61% 11.22% 7.58%
Return on Invested Capital (ROIC)		 6,197.00% 658.11% -428.01% -17.42% 22.19% -5.56% -46.02% 10.83% 23.36% -5.55%
ROIC Less NNEP Spread (ROIC-NNEP)		 6,196.04% 656.79% -427.13% -19.06% 20.07% -6.01% -46.82% 9.30% 21.69% -7.25%
Return on Net Nonoperating Assets (RNNOA)		 -6,101.99% -595.56% 357.76% 14.43% -15.68% 4.61% 36.86% -7.41% -17.51% 6.00%
Return on Equity (ROE)		 95.01% 62.55% -70.25% -2.99% 6.51% -0.95% -9.15% 3.42% 5.85% 0.45%
Cash Return on Invested Capital (CROIC)		 29.08% 0.52% 133.48% 79.97% 51.27% 35.49% -10.61% -22.30% -34.98% -7.64%
Operating Return on Assets (OROA)		 27.97% 24.38% -40.42% -1.15% 3.89% -6.09% -9.16% 2.57% 3.91% -1.65%
Return on Assets (ROA)		 29.07% 26.20% -34.36% 2.67% 7.53% 0.09% -4.15% 3.95% 5.59% 2.74%
Return on Common Equity (ROCE)		 95.01% 62.55% -70.25% -2.99% 6.51% -0.95% -9.15% 3.42% 5.85% 0.45%
Return on Equity Simple (ROE_SIMPLE)		 64.97% 0.00% 41.86% 19.17% 10.10% 0.00% 1.49% 2.67% 3.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 61 63 -21 -2.78 5.17 -1.87 -12 3.97 8.95 -1.51
NOPAT Margin		 36.44% 34.10% -45.12% -4.61% 7.44% -3.36% -24.49% 5.38% 11.10% -2.10%
Net Nonoperating Expense Percent (NNEP)		 0.96% 1.32% -0.89% 1.64% 2.11% 0.45% 0.80% 1.53% 1.66% 1.70%
Return On Investment Capital (ROIC_SIMPLE)		 - 7.84% - - - -0.22% - - - -0.18%
Cost of Revenue to Revenue		 36.57% 42.00% 31.35% 22.47% 19.03% 15.63% 21.59% 16.24% 16.23% 18.62%
SG&A Expenses to Revenue		 19.10% 16.81% 77.88% 61.53% 54.74% 74.25% 86.76% 56.46% 53.41% 57.73%
R&D to Revenue		 7.73% 6.97% 28.99% 21.65% 20.31% 25.40% 26.64% 20.26% 17.86% 25.92%
Operating Expenses to Revenue		 26.83% 23.78% 133.11% 83.18% 73.61% 99.64% 113.39% 76.72% 71.27% 83.65%
Earnings before Interest and Taxes (EBIT)		 61 63 -29 -1.48 7.38 -14 -19 7.40 12 -4.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 63 62 -30 -3.46 5.20 -18 -22 5.45 11 -4.83
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.64 2.34 2.22 2.88 3.14 2.90 2.59 2.29 2.14 2.81
Price to Tangible Book Value (P/TBV)		 2.65 2.34 2.23 2.89 3.16 2.91 2.60 2.29 2.15 2.82
Price to Revenue (P/Rev)		 1.80 1.88 1.91 3.61 5.27 7.78 6.79 5.89 5.60 6.05
Price to Earnings (P/E)		 4.12 4.64 5.31 15.04 31.27 0.00 173.95 85.57 71.29 61.47
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 24.28% 21.57% 18.82% 6.65% 3.20% 0.00% 0.57% 1.17% 1.40% 1.63%
Enterprise Value to Invested Capital (EV/IC)		 7.06 5.36 6.16 10.21 13.14 12.56 9.36 7.34 6.52 11.13
Enterprise Value to Revenue (EV/Rev)		 1.30 1.32 1.25 2.61 3.89 5.54 4.67 3.84 3.53 4.29
Enterprise Value to EBITDA (EV/EBITDA)		 2.89 3.32 3.69 13.14 41.87 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 2.96 3.35 3.67 12.73 34.85 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 3.17 3.38 3.72 13.44 41.58 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.44 15.22 5.84 7.89 11.54 12.80 19.61 24.60 33.72 17.87
Enterprise Value to Free Cash Flow (EV/FCFF)		 24.29 1,037.87 8.92 12.35 22.63 25.85 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.44 0.38 0.39 0.38 0.37 0.36 0.36 0.35 0.33 0.38
Long-Term Debt to Equity		 0.44 0.38 0.39 0.38 0.37 0.36 0.36 0.35 0.33 0.38
Financial Leverage		 -0.98 -0.91 -0.84 -0.76 -0.78 -0.77 -0.79 -0.80 -0.81 -0.83
Leverage Ratio		 3.38 2.52 2.32 1.96 1.78 1.65 1.65 1.60 1.58 1.63
Compound Leverage Factor		 3.53 2.72 1.93 -5.56 3.42 -0.11 0.99 3.22 2.55 -2.92
Debt to Total Capital		 30.66% 27.61% 28.24% 27.79% 26.88% 26.36% 26.50% 25.78% 24.70% 27.28%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 30.66% 27.61% 28.24% 27.79% 26.88% 26.36% 26.50% 25.78% 24.70% 27.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 69.34% 72.39% 71.76% 72.21% 73.12% 73.64% 73.50% 74.22% 75.30% 72.72%
Debt to EBITDA		 0.67 0.77 0.99 2.43 6.63 -4.79 -5.89 -7.72 -9.63 -21.69
Net Debt to EBITDA		 -1.11 -1.40 -1.93 -5.03 -14.85 11.18 13.23 17.70 23.27 47.47
Long-Term Debt to EBITDA		 0.67 0.77 0.99 2.43 6.63 -4.79 -5.89 -7.72 -9.63 -21.69
Debt to NOPAT		 0.74 0.78 1.00 2.49 6.58 -8.59 -7.73 -15.12 -24.08 -61.36
Net Debt to NOPAT		 -1.21 -1.43 -1.95 -5.14 -14.74 20.05 17.36 34.70 58.22 134.30
Long-Term Debt to NOPAT		 0.74 0.78 1.00 2.49 6.58 -8.59 -7.73 -15.12 -24.08 -61.36
Altman Z-Score		 1.96 2.58 1.97 2.81 3.12 2.73 2.42 2.32 2.35 2.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.82 6.11 9.07 17.78 15.40 13.81 15.20 14.18 13.23 10.80
Quick Ratio		 2.94 5.14 8.27 16.20 14.14 12.65 13.74 12.84 11.98 9.67
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -201 -219 -150 5.08 33 74 3.06 -8.93 -25 -5.86
Operating Cash Flow to CapEx		 4,805.62% 2,202.14% 2,152.92% 3,734.49% 8,970.89% 798.96% -2,226.84% 1,375.22% 1,446.29% 1,524.18%
Free Cash Flow to Firm to Interest Expense		 -119.08 -129.80 -88.84 3.01 19.79 43.65 1.80 -5.26 -14.79 -3.44
Operating Cash Flow to Interest Expense		 36.53 20.75 16.38 16.61 18.41 8.14 -9.84 6.31 11.46 31.15
Operating Cash Flow Less CapEx to Interest Expense		 35.77 19.81 15.62 16.17 18.20 7.12 -10.28 5.85 10.67 29.10
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.76 0.71 0.66 0.47 0.37 0.23 0.24 0.26 0.26 0.28
Accounts Receivable Turnover		 4.42 5.17 5.42 4.18 4.06 2.42 3.13 4.62 4.27 6.06
Inventory Turnover		 3.04 4.34 3.47 2.63 1.57 0.89 0.78 0.78 0.80 0.80
Fixed Asset Turnover		 21.07 19.90 17.58 12.46 10.10 6.20 6.33 6.79 7.09 7.27
Accounts Payable Turnover		 77.84 90.23 17.24 40.72 38.56 11.87 9.54 11.50 8.76 6.91
Days Sales Outstanding (DSO)		 82.50 70.54 67.31 87.24 89.93 150.89 116.71 78.92 85.47 60.19
Days Inventory Outstanding (DIO)		 119.87 84.08 105.33 138.80 233.21 410.12 469.80 469.99 456.27 455.26
Days Payable Outstanding (DPO)		 4.69 4.05 21.18 8.96 9.47 30.76 38.24 31.73 41.66 52.80
Cash Conversion Cycle (CCC)		 197.68 150.58 151.46 217.07 313.68 530.24 548.27 517.18 500.08 462.65
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 135 178 133 118 107 102 118 131 141 107
Invested Capital Turnover		 170.05 19.30 9.49 3.78 2.98 1.66 1.88 2.01 2.10 2.65
Increase / (Decrease) in Invested Capital		 262 282 129 -7.85 -28 -76 -15 13 34 4.35
Enterprise Value (EV)		 955 955 823 1,201 1,404 1,287 1,104 958 919 1,189
Market Capitalization		 1,320 1,358 1,253 1,660 1,902 1,807 1,604 1,470 1,460 1,679
Book Value per Share		 $3.96 $4.55 $4.42 $4.49 $4.70 $4.81 $4.75 $4.91 $5.20 $4.54
Tangible Book Value per Share		 $3.94 $4.54 $4.40 $4.48 $4.68 $4.80 $4.73 $4.90 $5.18 $4.53
Total Capital		 722 803 786 799 827 845 841 866 905 821
Total Debt		 221 222 222 222 222 223 223 223 224 224
Total Long-Term Debt		 221 222 222 222 222 223 223 223 224 224
Net Debt		 -365 -403 -430 -459 -498 -520 -501 -512 -540 -490
Capital Expenditures (CapEx)		 1.28 1.59 1.28 0.75 0.35 1.72 0.75 0.78 1.35 3.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 102 143 87 71 61 55 72 84 92 56
Debt-free Net Working Capital (DFNWC)		 689 767 739 753 781 797 795 820 856 770
Net Working Capital (NWC)		 689 767 739 753 781 797 795 820 856 770
Net Nonoperating Expense (NNE)		 -2.68 -4.82 3.16 -6.21 -9.12 -2.09 -3.72 -7.42 -8.64 -8.56
Net Nonoperating Obligations (NNO)		 -365 -403 -430 -460 -498 -520 -501 -512 -540 -490
Total Depreciation and Amortization (D&A)		 1.66 -0.76 -1.84 -1.97 -2.18 -3.28 -2.58 -1.96 -1.37 -0.58
Debt-free, Cash-free Net Working Capital to Revenue		 13.96% 19.72% 13.22% 15.47% 16.89% 23.52% 30.38% 33.72% 35.36% 20.37%
Debt-free Net Working Capital to Revenue		 93.95% 106.12% 112.66% 163.82% 216.35% 343.08% 336.77% 328.33% 328.29% 277.84%
Net Working Capital to Revenue		 93.95% 106.12% 112.66% 163.82% 216.35% 343.08% 336.77% 328.33% 328.29% 277.84%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.50 $0.54 ($0.19) $0.03 $0.11 $0.00 ($0.07) $0.09 $0.13 $0.06
Adjusted Weighted Average Basic Shares Outstanding		 127.06M 126.40M 127.92M 128.63M 128.99M 128.73M 130.20M 130.92M 131.13M 130.05M
Adjusted Diluted Earnings per Share		 $0.43 $0.45 ($0.19) $0.03 $0.10 $0.01 ($0.07) $0.08 $0.12 $0.07
Adjusted Weighted Average Diluted Shares Outstanding		 151.54M 150.80M 127.92M 152.14M 154.20M 128.73M 130.20M 154.47M 154.81M 133.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 127.58M 127.69M 128.49M 128.80M 129.26M 130.61M 130.89M 131.04M 131.45M 124.07M
Normalized Net Operating Profit after Tax (NOPAT)		 61 63 -21 -2.78 2.88 -5.94 -12 3.97 8.95 -1.51
Normalized NOPAT Margin		 36.44% 34.10% -45.12% -4.61% 4.14% -10.69% -24.49% 5.38% 11.10% -2.10%
Pre Tax Income Margin		 38.21% 36.84% -50.54% 6.98% 20.35% 1.79% -22.64% 20.20% 24.58% 10.59%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 36.44 37.43 -16.98 -0.88 4.36 -8.54 -11.37 4.36 7.23 -2.50
NOPAT to Interest Expense		 36.28 37.36 -12.56 -1.65 3.06 -1.10 -7.34 2.34 5.27 -0.89
EBIT Less CapEx to Interest Expense		 35.68 36.49 -17.74 -1.32 4.16 -9.56 -11.81 3.90 6.44 -4.54
NOPAT Less CapEx to Interest Expense		 35.52 36.42 -13.32 -2.09 2.85 -2.12 -7.78 1.88 4.48 -2.93
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 366.18%

Frequently Asked Questions About Dynavax Technologies' Financials

When does Dynavax Technologies's fiscal year end?

According to the most recent income statement we have on file, Dynavax Technologies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Dynavax Technologies' net income changed over the last 10 years?

Dynavax Technologies' net income appears to be on a downward trend, with a most recent value of $27.31 million in 2024, falling from -$90.72 million in 2014. The previous period was -$6.39 million in 2023. See Dynavax Technologies' forecast for analyst expectations on what’s next for the company.

What is Dynavax Technologies's operating income?
Dynavax Technologies's total operating income in 2024 was -$4.12 million, based on the following breakdown:
  • Total Gross Profit: $227.80 million
  • Total Operating Expenses: $231.92 million
How has Dynavax Technologies revenue changed over the last 10 years?

Over the last 10 years, Dynavax Technologies' total revenue changed from $11.03 million in 2014 to $277.25 million in 2024, a change of 2,413.1%.

How much debt does Dynavax Technologies have?

Dynavax Technologies' total liabilities were at $389.46 million at the end of 2024, a 3.8% increase from 2023, and a 930.1% increase since 2014.

How much cash does Dynavax Technologies have?

In the past 10 years, Dynavax Technologies' cash and equivalents has ranged from $24.29 million in 2016 to $436.19 million in 2021, and is currently $95.88 million as of their latest financial filing in 2024.

How has Dynavax Technologies' book value per share changed over the last 10 years?

Over the last 10 years, Dynavax Technologies' book value per share changed from 0.38 in 2014 to 4.54 in 2024, a change of 1,087.9%.


Related Companies

This page (NASDAQ:DVAX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...
Weiss Ratings | Sponsored